Dasatinib is a dual kinase inhibitor that acts on c-Src and Abl kinases; because these kinases are dysregulated in the pathogenesis of CML, it is a very specific anticancer drug for treating cancers such as CML [83]. Here, SRC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.